Business Wire

Lightricks’ LTX Studio, the AI Visual Storytelling Platform, Now Open to All

20.8.2024 14:01:00 CEST | Business Wire | Press Release

Share

Lightricks, the AI innovators behind Facetune, Videoleap, Photoleap and Popular Pays, announced today that LTX Studio beta, the first AI-driven storyboarding and prototyping platform, is now open to the public. The platform, designed for creative film and marketing professionals, offers real-time, intuitive generative and editing solutions. This announcement includes new features that push the boundaries of visual storytelling, such as increased character and frame control and multi-user collaboration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240820994937/en/

The LTX Studio platform integrates proprietary AI research from Lightricks engineers with the latest licensed and open-source generative AI models, redefining the creative process. It streamlines video production planning and execution, empowering a wide range of creative professionals—from individual filmmakers to large production companies and advertising agencies—to develop, visualize, storyboard, and pitch their creative concepts into fully crafted film and video projects with unprecedented efficiency and control.

“Releasing LTX Studio to everyone demonstrates our ongoing commitment to the future of video creation through innovative AI-driven tools and our belief in generative AI as a powerful market changer," said Zeev Farbman, CEO and co-founder of Lightricks. “We’ve worked closely with our design partners and creator community to ensure our platform meets their diverse needs better than anything else on the market. We remain committed to exploring new technology and enhancing LTX Studio’s capabilities.”

LTX Studio’s suite of AI features has been refined based on technical and creative feedback from our creative community of more than 35,000 members. The latest updates focus on:

  • Enhanced Collaboration: The new Collaboration feature enables creative teams to work together more efficiently with live edit views. LTX Studio plans to release additional collaborative tools, such as commenting and suggestion capabilities, soon.
  • Character Acting: LTX Studio now syncs realistic voices with lip movements for any character, allowing users to customize facial gestures and dialogues by referencing real human videos. Users can generate voice from text using AI or upload their original voice files. Future updates will include voice switching for character dialogue and complete scene editing with dialogues.
  • Generation Control: Users can now enjoy more control and accuracy in creating their wanted frames and desired motion. Frame Creator lets users craft frames using prompts and scribbles. Keyframe Control generates frames between defined start and end points.

Case Study: Recently, financial services company eToro used LTX Studio to create an AI-generated advertisement that aired during the Paris Olympics. This showcased LTX Studio’s ability to produce high-quality, realistic video content, demonstrating how brands can easily leverage LTX Studio to create compelling visual stories.

Pricing: LTX Studio now offers a tiered pricing model. Users can experience the platform for free with limited generative AI capability, or select from a range of plans based on their monthly generative time needs. Custom plans with premium features are available for enterprises and larger organizations and teams.

Lightricks is embarking on a prolific roadmap for LTX Studio leading into 2025, focusing on leveraging AI to innovate the visual storytelling experience and fuel creativity for professional creators globally. To experience LTX Studio today, join at LTX.Studio.

About Lightricks

Lightricks, an AI-first company, is revolutionizing how visual content is created. With a mission to bridge the gap between imagination and creation, Lightricks is dedicated to bringing cutting-edge technology to the creative and business spaces.

Our AI photo and video generation models, which power our apps and platforms including Facetune, Photoleap, Videoleap, and LTX Studio, allow creators and brands to leverage the latest research breakthroughs, offering endless control over their creative potential. Our influencer marketing platform, Popular Pays, provides creators the ability to monetize their work and offers brands opportunities to scale their content through tailored creator partnerships.

Founded in 2013, Lightricks is backed by prominent investors including Goldman Sachs Growth Equity, Insight Partners and Viola Ventures, who share Lightricks’ enduring commitment to driving the future of content creation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820994937/en/

Contacts

Olivia Knecht
lightricks@clarity.global

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye